Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis

Joint Bone Spine

Volumn 79, Issue 5, 2012, Pages 510-513

  Rueda Gotor, Javier ^a   González Gay, Miguel A ^a   Blanco Alonso, Ricardo ^a   Gonzalez Vela, Carmen ^a   Lopez Obregon, Cristina ^a   González López, Marcos A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Adalimumab; Palmoplantar pustulosis; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; CORTICOSTEROID; ETRETIN; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TOCILIZUMAB; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MALAISE; MONOTHERAPY; PHYSICAL EXAMINATION; PRESCRIPTION; PSORIASIS; PUNCH BIOPSY; PUSTULOSIS PALMOPLANTARIS; REMISSION; RHEUMATOID ARTHRITIS; SKIN DEFECT; SMOKING; SYNOVITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MIDDLE AGED; PSORIASIS; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 84867981249     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.06.010     Document Type: Article

References (19)

1. Braun J., Kalden J.R. Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009, 27:S164-S167.
2. Wakabayashi H., Oka H., Nishioka Y., et al. Do biologics-naïve patients with rheumatoid arthritis respond better to tocilizumab than patients for whom anti-TNF agents have failed? A retrospective study. Clin Exp Rheumatol 2011, 29:314-317.
3. Mourão A.F., Rustin M., Isenberg D. Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy: description of three cases and review of the literature. Clin Exp Rheumatol 2010, 28:408-410.
4. Wendling D., Balblanc J.C., Briançon D., et al. Onset or exacerbation of cutaneous psoriasis during TNF-alpha antagonist therapy. Joint Bone Spine 2008, 75:315-318.
5. Wollina U., Hansel G., Koch A., et al. Tumor necrosis factor-α inhibitor-induced psoriasis or psoriasiform exanthemata first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008, 9:1-14.
6. Harrison M.J., Dixon W.G., Watson K.D., et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor a therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009, 68:209-215.
7. Flendrie M., Vissers W.H., Creemers M.C., et al. Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005, 7:R666-R676.
8. Collamer A.N., Guerrero K.T., Henning J.S., et al. Psoriatic skin lesions induced by tumour necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008, 59:996-1001.
9. Jung N., Hellmann M., Hoheisel R., et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 2010, 29:1169-1173.
10. Moberg P., Charles J.F., Respicio G., et al. Improvement in psoriasis during rituximab therapy for mixed cryoglobulinemia type II. Cutis 2010, 86:133-135.
11. Castells-Rodellas A., Castell J.V., Ramirez-Bosca A., et al. Interleukin-6 in normal skin and psoriasis. Acta Derm Venereol 1992, 72:165-168.
12. Goodman W.A., Levine A.D., Massari J.V., et al. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009, 183:3170-3176.
13. Bonifati C., Carducci M., Cordiali Fei P., et al. Correlated increases of tumour necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients relationship with disease severity. Clin Exp Dermatol 1994, 19:383-387.
14. Ameglio F., Bonifati C., Pietravalle M., et al. Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy. Dermatology 1994, 189:359-363.
15. Burger D., Begué-Pastor N., Benavent S., et al. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford) 2003, 42:89-96.
16. Brulhart L., Nissen M.J., Chevallier P., et al. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 2010, 77:616-627.
17. Ogata A., Umegaki N., Katayama I., et al. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 2012, 79:85-87.
18. Laurent S., Le Parc J.M., Clerici T., et al. Onset of psoriasis following treatment with tocilizumab. Br J Dermatol 2010, 136:1364-1365.
19. Wendling D., Letho-Gyselinck H., Guillot X., et al. Psoriasis onset with tocilizumab treatment for rheumatoid arthritis. J Rheumatol 2012, 39:657.